Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial

医学 耐受性 安慰剂 临床试验 伤口愈合 加药 生理盐水 随机对照试验 不利影响 外科 麻醉 内科学 病理 替代医学
作者
Emelie Öhnstedt,Evelina Vågesjö,Andreas E. R. Fasth,Hava Lofton Tomenius,Pia Dahg,Sofia Jönsson,Nisha Tyagi,Mikael Åström,Zhanar Myktybekova,Lovisa Ringstad,Margareth Jorvid,Peter Frank,Per Hedén,Stefan Roos,Mia Phillipson
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:60: 102014-102014 被引量:24
标识
DOI:10.1016/j.eclinm.2023.102014
摘要

Summary

Background

Impaired wound healing is a growing medical problem and very few approved drugs with documented clinical efficacy are available. CXCL12-expressing lactic acid bacteria, Limosilactobacillus reuteri (ILP100-Topical), has been demonstrated to accelerate wound healing in controlled preclinical models. In this first-in-human study, the primary objective was to determine safety and tolerability of the drug candidate ILP100-Topical, while secondary objectives included assessments of clinical and biologic effects on wound healing by traditionally accepted methods and explorative and traceable assessments.

Methods

SITU-SAFE is an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial (EudraCT 2019-000680-24) consisting of a single (SAD) and a multiple ascending dose (MAD) part of three dose cohorts each. The study was performed at the Phase 1 Unit, Uppsala University Hospital, Uppsala, Sweden. Data in this article were collected between Sep 20th, 2019 and Oct 20th 2021. In total 240 wounds were induced on the upper arms in 36 healthy volunteers. SAD: 12 participants, 4 wounds (2/arm), MAD: 24 participants, 8 wounds (4/arm). Wounds in each participant were randomised to treatment with placebo/saline or ILP100-Topical.

Findings

In all individuals and doses, ILP100-Topical was safe and well-tolerated with no systemic exposure. A combined cohort analysis showed a significantly larger proportion of healed wounds (p = 0.020) on Day 32 by multi-dosing of ILP100-Topical when compared to saline/placebo (76% (73/96) and 59% (57/96) healed wounds, respectively). In addition, time to first registered healing was shortened by 6 days on average, and by 10 days at highest dose. ILP100-Topical increased the density of CXCL12+ cells in the wounds and local wound blood perfusion.

Interpretation

The favourable safety profile and observed effects on wound healing support continued clinical development of ILP100-Topical for the treatment of complicated wounds in patients.

Funding

Ilya Pharma AB (Sponsor), H2020 SME Instrument Phase II (#804438), Knut and Alice Wallenberg foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zheng完成签到 ,获得积分10
2秒前
yy14207发布了新的文献求助10
3秒前
duoduozs完成签到,获得积分10
3秒前
一白完成签到 ,获得积分10
3秒前
迷路凌柏完成签到 ,获得积分10
5秒前
江雁完成签到,获得积分10
5秒前
木子李完成签到 ,获得积分10
5秒前
2012csc完成签到 ,获得积分0
5秒前
英俊枫完成签到,获得积分10
7秒前
wbb完成签到 ,获得积分10
9秒前
竹叶青发布了新的文献求助10
9秒前
欢喜藏今完成签到,获得积分10
10秒前
YYYYYY完成签到,获得积分10
11秒前
15秒前
halo完成签到,获得积分10
16秒前
凌晨五点的完成签到,获得积分10
16秒前
斯文败类应助WPY1采纳,获得10
17秒前
赟yun完成签到,获得积分0
18秒前
爆米花应助222采纳,获得10
19秒前
一氧化二氢完成签到,获得积分10
19秒前
舒仲完成签到,获得积分10
20秒前
青柠完成签到 ,获得积分10
20秒前
21秒前
22秒前
木木完成签到,获得积分10
24秒前
丹丹完成签到 ,获得积分10
24秒前
贪玩路灯完成签到 ,获得积分10
25秒前
Hunter完成签到,获得积分10
26秒前
叶落无痕、完成签到,获得积分10
27秒前
大叉烧完成签到,获得积分10
27秒前
标致玉米发布了新的文献求助10
27秒前
Ivy完成签到,获得积分10
29秒前
30秒前
傲娇的云朵完成签到,获得积分10
30秒前
starwan完成签到 ,获得积分10
31秒前
KH发布了新的文献求助10
32秒前
唠叨的白曼完成签到,获得积分10
32秒前
33秒前
文艺水风完成签到 ,获得积分10
36秒前
糊涂的服饰完成签到,获得积分10
36秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968578
求助须知:如何正确求助?哪些是违规求助? 3513400
关于积分的说明 11167585
捐赠科研通 3248853
什么是DOI,文献DOI怎么找? 1794499
邀请新用户注册赠送积分活动 875131
科研通“疑难数据库(出版商)”最低求助积分说明 804664